Outcomes Of Treating Tuberculosis Patients With Drug-resistant Tuberculosis, Human Immu-nodeficiency Virus, And Nutritional Status: The Combined Impact Of Triple Challenges In Rural Eastern Cape

Background: Treatment outcomes are vital measures of the success of TB treatment programs, especially in areas with limited re-sources, as tuberculosis continues to be a major public health issue. The study aimed to evaluate clinical data from TB-infected pa-tients' clinic files in rural areas of the Olivier Reginald Tambo District Municipality, Eastern Cape, South Africa, to understand the treatment outcomes of tuberculosis in patients with drug-resistant tuberculosis, human immunodeficiency virus, and nutritional status. Methods: The study analyzed 360 patient files to investigate the treatment outcomes of patients with drug-resistant tuberculosis (DR-TB) and HIV, as well as a body mass index (BMI) indicating moderate to severe classification. The data included patient de-mographics, clinical characteristics, and social history. The study also detailed and analyzed culture conversion, time in treatment, and treatment outcomes. Additionally, BMI data were presented using a scatter plot to display the distribution of BMI across different age groups and genders to identify patterns and trends in obesity prevalence. Results: The study demonstrated the high rates of both overweight and underweight individuals among middle-aged and elderly people, emphasizing the need for personalized nutritional interventions. It found that Type 1 (RR-TB) and Type 2 (MDR-TB) were the most common forms of DR-TB, with a higher prevalence of HIV-positive individuals in Type 1 (RR-TB). The study also showed the distribution of different BMI categories among DR-TB types and HIV statuses. Overall, it suggests limited connections between DR-TB type, BMI category, and HIV status in the research. Conclusion: It is imperative to prioritize the management of co-morbid conditions in DR-TB patients, as these conditions signifi-cantly influence treatment outcomes. Targeted interventions are essential for patients with severe or complex co-morbidities.